Pharmaceuticals

Tsingke Highlights How Biotech Teams Can Evaluate and Advance Antibody Candidates at PEGS Europe 2026

From early antibody hits to engineered formats and antibody–oligonucleotide conjugates, Tsingke helps R&D teamsgenerate the data they need to make the next development decision. LISBON, Portugal, Nov. 20, 2026 /PRNewswire/ -- An antibody that binds its target is a starting point for drug discove...

2026-11-20 22:18 2190

Sun Yat-sen University Marks 160 Years of Medical Education and Sets Out Its Next Priorities

GUANGZHOU, China, Nov. 20, 2026 /PRNewswire/ -- Sun Yat-sen University (SYSU) marked the 160th anniversary of its medical education at an anniversary forum in Guangzhou on November 8. Tracing its medical roots to the founding of Boji Medical School in 1866, SYSU has evolved over the past 160 year...

2026-11-20 21:00 1489

PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026

– No dose-limiting toxicities observed across doses from 10 to 750 mg, with no PT0253-specific pre-treatment prophylaxis required – – Monotherapy antitumor activity observed in colorectal and pancreatic cancers, including a partial response in a patient previously treated with a KRAS-targeted ag...

2026-11-20 20:00 1751

Everest Medicines Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD

SHANGHAI, Nov. 20, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, announced that the first patient has been treated in ...

2026-11-20 13:00 1642

Registrational Phase III AMPLIFY trial: Follow-up assessments completed for all participants

SYDNEY, Nov. 19, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the last patient...

2026-11-19 22:02 2324

Innogen Pharmaceuticals Enters into Licensing Agreement with Arcera Life Sciences for Efsubaglutide Alfa, Accelerating International Expansion

* Under the agreement, Arcera will obtain exclusive rights to Efsubaglutide Alfa in selected countries in Africa, Latin America, the Middle East and Eastern Europe, while Innogen retains the relevant rights in the rest of the world. * Under the agreement, Innogen will receive US$38 million in...

2026-11-19 18:05 1568

Community Med Care Marks 8th Anniversary, Providing 55,058 Free TCM Treatments to 1,288 Children with Chronic Illnesses or Special Needs

Charity highlights its Dream Realization Project and calls for greater public awareness and sustained community support for children's long-term rehabilitation and their caregivers HONG KONG, Nov. 19, 2026 /PRNewswire/ -- Community Med Care marks its eighth anniversary this year, having provided...

2026-11-19 13:57 1019

DNV supports FAMID Biomedical Technology in achieving IVDR certification for its Class C IVD in six months

Certification supports European market access for a diagnostic test designed to aid the diagnosis of cervical precancerous lesions. HOVIK, Norway, Nov. 19, 2026 /PRNewswire/ -- DNV, an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation (IVDR), has issued an IVDR certificate ...

2026-11-19 09:00 1430

Harbour BioMed Announces NMPA Acceptance of IND Application for Its First AI-Enabled Drug Candidate LET003 for the Treatment of Overweight or Obesity

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced ...

2026-11-19 08:01 1632

/DISREGARD RELEASE: NeuroGen/

We are advised by NeuroGen that journalists and other readers should disregard the news release, China's First CGRP Targeted Therapy to Enter the NRDL: NeuroGen Officially Launches Ajovy® (fremanezumab), Benefiting the First Cohort of Migraine Patients, issued 18-Nov-2026 over PR Newswire. The...

2026-11-19 00:10 1708

Fapon Connects Enzyme Innovation with Real-World Applications at AMP 2026

Fapon-hosted workshop highlights AI-powered enzyme engineering and application insights from full-length transcriptomics SEATTLE, Nov. 18, 2026 /PRNewswire/ -- Fapon, a globally leading life sciences organization, has concluded its participation in the Association for Molecular Pathology (AMP) 2...

2026-11-18 21:50 1053

PharmaResearch Global Symposium Draws More Than 750 Clinicians From 64 Countries

The seventh symposium in Gangneung, South Korea, featured clinical research on REJURAN® polynucleotides and a behind-the-scenes look at how the products are made GANGNEUNG, South Korea, Nov. 18, 2026 /PRNewswire/ -- PharmaResearch, the Korean pharmaceutical company behind the globally recognized...

2026-11-18 21:30 1241

Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia

Single-cycle bridge-to-transplant trial builds on two prior AML studies of bisantrene at Sheba; Phase 2b dose-optimization stage (up to 68 patients) funded from existing cash, with first patient dosing expected in Q1 2027; RC220 holds FDA Orphan Drug Designation in AML SYDNEY, Nov. 18, 2026 /PRN...

2026-11-18 20:37 1180

LOTTE Biologics Holds Completion Ceremony for Songdo Bio Campus

"A New Horizon for K-Bio" * Completion ceremony for Plant 1 of the Songdo Bio Campus, securing a biopharmaceutical production facility with 120,000 liters of capacity * Leveraging large-scale production infrastructure and hands-on operating experience in the U.S., the company moves to strengt...

2026-11-18 19:33 964

Harbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone Company

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced ...

2026-11-18 08:02 1615

TriNetX Names Carnell Elliott Chief Commercial Officer

Healthcare technology leader who scaled commercial teams at Henry Schein One and Change Healthcare joins TriNetX's executive team CAMBRIDGE, Mass., Nov. 17, 2026 /PRNewswire/ -- TriNetX®, the world's leading federated health data network, today announced the appointment of Carnell Elliott as Chi...

2026-11-17 21:27 1221

Daewoong Pharmaceutical Presents Phase 1 Clinical Trial Data for New Autoimmune Disease Drug 'Plodicitinib' at ACR Convergence 2026

* Presented at the American College of Rheumatology (ACR) conference… Confirmed over 90% BTK and ITK target coverage, securing early pharmacodynamic evidence * Distinctive mechanism that simultaneously modulates T cells and B cells… Potential for development across a wide range of autoimmune...

2026-11-17 21:00 1452

Isomorphic Labs announces $5 Billion Series C funding

Greenoaks and Sequoia Capital co-lead the oversubscribed round as Isomorphic Labs continues to advance its foundational simulation models, progress and scale its internal and partnered medicine candidate pipeline, and build its global AI-led bioengineering infrastructure LONDON, Nov. 17, 2026 /P...

2026-11-17 20:38 1521

Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Bridging Study, Linking RC220 to Prior Clinical Experience in AML

Exposure ratios met pre-specified equivalence criteria on all three dosing days, supporting use of the established RC110 clinical dataset and dosing levels for RC220, including in the Phase 2b/3 EMILI trial in acute myeloid leukemia SYDNEY, Nov. 17, 2026 /PRNewswire/ -- Racura Oncology Ltd (ASX:...

2026-11-17 20:00 1957

LOTTE Biologics Secures Major Commercial Manufacturing Agreement Ahead of Songdo Plant 1 Launch

* Landmark deal validates commercial strategy and reinforces confidence in LOTTE Biologics' advanced manufacturing capabilities * Establishes a commercial manufacturing partnership upon completion of the plant, with full-scale commercial production to begin in 2027 * Accelerates 'Dual-Site'...

2026-11-17 19:22 1196
12345 ... 351